High Efficacy Reported for Sputnik V COVID-19 Vaccine
Interim analysis of data from phase 3 trial shows 91.6 percent efficacy at 21 days after the first dose of the vaccine
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.